Development Of A Nanobody-conjugate Platform For Targeted Drug Delivery In Airway Hypersecretory Diseases (AHDs)

Mucus hypersecretion is a common pathophysiology in airway diseases. To this date, very few treatments focus on this symptom alone. This project focusses on the development of a new platform targeting the mucin pathway to regulate mucus hypersecretion. New technologies such as nanobodies allow for the targeting of specific molecules, and liposomes or alternative bioconjugates facilitate the delivery of chemical compounds to the required site. This new platform will employ those technologies to create a targeted solution to mucus hypersecretion.